Concurrent Olaparib and Radiation Therapy for BRCA2-Mutated Breast Cancer

Data regarding the safety of concurrent olaparib and radiation therapy in patients with BRCA1/2-mutated breast cancer are very limited. We report the case of a 45-year-old woman treated with concurrent adjuvant olaparib and radiation therapy for a recurrent BRCA2-mutated breast cancer presenting with a synchronous advanced-stage ovarian cancer. The patient received standard-dose locoregional radiation therapy to the ipsilateral breast, axilla, supraclavicular region, and internal mammary chain, with concurrent reduced-dose olaparib. The treatment was well tolerated with no unexpected acute toxicity. Further clinical trials are needed to confirm the safety and efficacy of concurrent olaparib and radiation therapy in this patient population.